AstraZeneca stock gains on Deutsche Bank upgrade and CEO share purchase

AstraZeneca PLC stock (ISIN GB0009895292) is trading near recent highs after a combination of an analyst upgrade and insider buying, with the shares closing at 12,500.0 pence on the London Stock Exchange on September 18, 2026 and Deutsche Bank nudging its price target to 11,700 pence.

Deutsche Bank upgrades AstraZeneca with higher target

According to Sharecast on September 15, 2026, Deutsche Bank upgraded AstraZeneca from sell to hold and raised its price target from 11,500 pence to 11,700 pence, arguing that the risk-reward profile had shifted after recent developments and a period of underperformance versus European large-cap peers.

This 200 pence increase in the target represents a 1.7 percent uplift versus the previous 11,500 pence level and places the new Deutsche Bank target roughly 6.4 percent below the 12,500.0 pence closing price recorded in London on September 18, 2026, highlighting that the stock is already trading above this specific analyst view.

CEO Pascal Soriot buys shares in mid-September

In parallel with the rating change, AstraZeneca's chief executive officer Pascal Soriot has increased his personal stake in the company. According to Sina Finance on September 20, 2026, Soriot bought 60,000 AstraZeneca shares on September 14, 2026 at an average price of USD 161.57 per share, for a total transaction value of about USD 9,694,200.

After this insider purchase, Soriot's total holding rose to 430,428 shares, corresponding to approximately 0.03 percent of AstraZeneca's outstanding share capital as reported in the same disclosure by Moomoo. For investors, such a multi-million dollar insider purchase at USD 161.57 per share is often interpreted as a signal of confidence in the company's medium-term prospects and may reinforce the positive sentiment from the Deutsche Bank upgrade.

Stock near 52-week high on London listing

AstraZeneca's primary listing is on the London Stock Exchange, where the stock closed at 12,500.0 pence on September 18, 2026, up 72.0 pence or 0.58 percent compared with the previous close, with an intraday range between 12,398.0 and 12,596.0 pence and a trading volume of 6.52 million shares, based on data cited by Ad-hoc-news from Investing.com.

The same report notes that AstraZeneca's 12,500.0 pence London closing price on September 18, 2026 leaves the shares trading below a 52-week high level of GBP 157.32, indicating that despite recent gains and the Deutsche Bank upgrade the stock still has room before retesting its yearly peak. In addition, US investors can access AstraZeneca via the NYSE-listed AZN American Depositary Receipts, where the tokenized representation recently traded around USD 166.08 according to Pluang, compared with Soriot's insider purchase level of USD 161.57.

Latest results context and analyst sentiment

While the current news flow is dominated by the Deutsche Bank upgrade and insider buying, AstraZeneca's recent performance also reflects its fundamental backdrop, including oncology and cardiovascular portfolios and ongoing clinical trials. According to Ad-hoc-news, the Deutsche Bank move came in the wake of data from the SERENA-4 lung cancer study, which affected sentiment but has now been digested by the market, with the bank viewing the risk-reward as more balanced at the current share price.

Price-data overviews from UK-focused portals show AstraZeneca among the larger London healthcare names with daily turnover in the millions of shares and a market capitalization that places it firmly in the blue-chip segment, while listings such as National Stock Exchange of India summaries still refer to the 12,500.0 pence London price and 6.52 million volume as of September 18, 2026, underscoring the global visibility of the stock per Investing.com UK.

Closing price and investor takeaway

As of September 18, 2026, the reference price for AstraZeneca stock on its primary London Stock Exchange listing stands at 12,500.0 pence, with the shares up 0.58 percent on that trading day and trading between 12,398.0 and 12,596.0 pence, while the stock remains below its noted 52-week high of GBP 157.32 and above Deutsche Bank's new 11,700 pence price target.

More news and analyses on AstraZeneca PLC stock